Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Futura Medical phase III trial on track to begin in September; out-licensing agreement "remains a top priority"

The company's flagship product is a fast-acting gel for erectile dysfunction
Futura Medical phase III trial on track to begin in September; out-licensing agreement "remains a top priority"
The company's condom range received regulatory sign-off in Kuwait recently

The phase III clinical trial of Futura Medical PLC's (LONFUM) fast-onset gel for erectile dysfunction is on track for first patient dosing in September, chairman John Clarke confirmed ahead of the company's annual meeting later.

He added that the completion of a significant out-licensing agreement for MED2002 "remains a top priority" as he investors were told: "Whilst negotiations proceed, we will continue to maintain the momentum in the product's development.

READ: Futura Medical starts work on Phase III trial for its erectile dysfunction gel

In an update on progress, Clarke said preparations for the launch of its CSD500 condom in new territories were underway after it received regulatory sign-off in Kuwait and with the product now on sale in Saudi Arabia. 

On TPR100, Futura's diclofenac gel for pain relief, the chairman said the company was waiting for the manufacturer Thornton & Ross to submit its UK regulatory dossier to the Medicines & Healthcare products Regulatory Agency.

"Futura has a strong balance sheet, an experienced team, an exciting product portfolio and a particularly valuable asset in MED2002, which has the potential to be the world's fastest-acting erectile dysfunction treatment," said Clarke.  

"We look forward to providing further updates in the current financial year."


View full FUM profile View Profile

Futura Medical PLC Timeline

Related Articles

man coughing
November 09 2018
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them
Artificial intelligence
October 29 2018
E-therapeutics believes it is now focused on the right activities
car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use